Rod-Derived Cone Viability Factor Fusion Protein
Summary
USPTO published patent application US20260091133A1 disclosing a fusion protein comprising rod-derived cone viability factor-S (RdCVF-S), a hydrophilic peptide, and a signal peptide. The invention covers encoding nucleic acids, viral vectors, and pharmaceutical compositions for potential treatment of ocular conditions. Inventors: Tianci LUO, Daniel LIPUT, Fong Qi LIANG. Application No. 19339969 filed September 25, 2025.
What changed
The USPTO published patent application US20260091133A1 on April 2, 2026, disclosing a fusion protein combining RdCVF-S with a hydrophilic peptide and signal peptide, along with encoding nucleic acids and viral vectors for delivery. The invention extends to pharmaceutical compositions and methods of treatment for cone viability. CPC classifications indicate applications in gene therapy (C12N 15/86) and therapeutic proteins (A61K 48/005). The application was filed as No. 19339969 on September 25, 2025.
Patent applicants and biotechnology companies should review this publication to assess potential freedom-to-operate implications in ocular gene therapy and therapeutic protein development. Competitors developing similar rod-derived cone viability factor proteins or viral vector delivery systems for ophthalmic applications should monitor this application through prosecution to identify any claim scope that may affect their R&D activities.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ROD-DERIVED CONE VIABILITY FACTOR FUSION PROTEIN
Application US20260091133A1 Kind: A1 Apr 02, 2026
Inventors
Tianci LUO, Daniel LIPUT, Fong Qi LIANG
Abstract
The present invention relates to a fusion protein comprising a) a short rod-derived cone viability factor (RdCVF-S), b) a hydrophilic peptide, and c) a signal peptide, along with the nucleic acids encoding those peptides and viral vectors containing these nucleic acids. The invention also relates to compositions and pharmaceutical preparations comprising these nucleic acids or vectors, methods of producing or secreting the fusion protein comprising RdCVF-S protein, an immunoglobulin constant region, and a human signal sequence, and methods of treatment.
CPC Classifications
A61K 48/005 A61K 48/0075 A61P 27/02 C07K 14/4702 C12N 15/62 C12N 15/86 A61K 38/00 C07K 2319/02 C07K 2319/30 C12N 2750/14143
Filing Date
2025-09-25
Application No.
19339969
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Biotech (C12N) publishes new changes.